Skip to content
Sign in

FMED · NASDAQ · ETF

Fidelity Disruptive Medicine ETF (FMED) Price, Holdings & Fees

$457.34+0.77%+$3.51End-of-day price as of Oct 9, 2026

Fidelity Disruptive Medicine ETF (FMED) closed at $457.34 on Oct 9, 2026, up 0.77% from the previous close of $453.83.

Share price, past year

1Y +25.13%

52-week range $352.44 – $460.21. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$457.34
Sep 30, 2026$447.40
Aug 31, 2026$436.73
Jul 31, 2026$430.07
Jun 30, 2026$439.40
May 29, 2026$420.51
Apr 30, 2026$428.24
Mar 31, 2026$403.08
Feb 27, 2026$411.16
Jan 30, 2026$398.54
Dec 31, 2025$395.65
Nov 28, 2025$361.71
Oct 31, 2025$364.49

Key statistics

Expense ratio
0.50%
as of Sep 30, 2025
Net assets
$41M
as of May 31, 2026
Holdings
70
as of May 31, 2026
52-week range
$352.44 – $460.21

Fidelity Disruptive Medicine ETF's expense ratio is 0.50%: $50.00 a year on $10,000 invested.

Holdings

Fidelity Disruptive Medicine ETF held 70 investments worth $40.98M as of May 31, 2026. Its largest holding was Fidelity Revere Street Trust, at 10.27% of the fund.

Fidelity Disruptive Medicine ETF largest holdings by share of net assets
#Holding% of fundValue
1Fidelity Revere Street Trust10.27%$4.21M
2UCB SA4.73%$1.94M
3LIFESTANCE HEALTH GROUP INC4.27%$1.75M
4DANAHER CORP3.42%$1.40M
510X GENOMICS INC3.11%$1.27M
6INTUITIVE SURGICAL INC2.92%$1.20M
7COGENT BIOSCIENCES INC2.85%$1.17M
8ALNYLAM PHARMACEUTICALS INC2.79%$1.14M
9ARGENX SE2.78%$1.14M
10LEGEND BIOTECH CORP2.29%$940.12K
11UNITEDHEALTH GROUP INC2.25%$921.87K
12BIO TECHNE CORP2.24%$919.18K
13ASCENDIS PHARMA A/S2.11%$866.19K
14EDWARDS LIFESCIENCES CORP2.11%$864.70K
15MODERNA INC2.11%$862.73K
16KYMERA THERAPEUTICS INC1.99%$814.20K
17XENON PHARMACEUTICALS INC1.92%$786.25K
18HEARTFLOW INC1.89%$774.31K
19SARTORIUS STEDIM BIOTECH1.84%$754.70K
20INSMED INC1.79%$735.01K
21VEEVA SYS INC1.78%$730.14K
22VAXCYTE INC1.77%$723.25K
23REVOLUTION MEDICINES INC1.73%$709.29K
24CARIS LIFE SCIENCES INC1.71%$702.09K
25CRINETICS PHARMACEUTICALS INC1.65%$675.45K

Top 25 of 70 holdings, as of May 31, 2026. Percentages are of the fund's net assets.

What the fund owns

Fidelity Disruptive Medicine ETF holdings by asset type
Asset type% of fund
Stocks99.73%
Cash and short-term investments10.56%
Fidelity Disruptive Medicine ETF holdings by country, largest 10
Country% of fund
United States88.17%
Belgium4.73%
Netherlands3.70%
Cayman Islands3.40%
Denmark2.11%
Canada1.92%
France1.84%
Bermuda1.78%
United Kingdom1.42%
Switzerland1.22%

Shares of net assets from the fund's N-PORT report. Funds that borrow can add up to more than 100%, with borrowing (such as repurchase agreements) shown as a negative share.

Monthly total returns

Over the 3 months to May 31, 2026, Fidelity Disruptive Medicine ETF's total return was −3.76%, as reported to the SEC.

Fidelity Disruptive Medicine ETF monthly total returns
MonthTotal return
May 31, 2026+1.64%
Apr 30, 2026+1.04%
Mar 31, 2026−6.29%

The fund's own total returns as reported to the SEC (N-PORT), including reinvested distributions. Not the sample prices above.

Fund profile

Name
Fidelity Disruptive Medicine ETF
Ticker
FMED
Exchange
NASDAQ
Fund type
ETF
Trust
FIDELITY COVINGTON TRUST
SEC series ID
S000079688
SEC CIK
0000945908
Fractional shares
No

Recent SEC filings

Shareholder reports and prospectuses are filed by FIDELITY COVINGTON TRUST, the trust behind Fidelity Disruptive Medicine ETF, and cover all of its funds.

Frequently asked questions

What is FMED's price?

Fidelity Disruptive Medicine ETF (FMED) closed at $457.34 on Oct 9, 2026, up 0.77% from the previous close of $453.83.

What is FMED's expense ratio?

Fidelity Disruptive Medicine ETF's expense ratio is 0.50%: $50.00 a year on $10,000 invested.

What does FMED hold?

Fidelity Disruptive Medicine ETF held 70 investments worth $40.98M as of May 31, 2026. Its largest holding was Fidelity Revere Street Trust, at 10.27% of the fund. Its five largest holdings were Fidelity Revere Street Trust, UCB SA, LIFESTANCE HEALTH GROUP INC, DANAHER CORP, 10X GENOMICS INC.

How has FMED performed?

Over the 3 months to May 31, 2026, Fidelity Disruptive Medicine ETF's total return was −3.76%, as reported to the SEC.

Sources and methodology

Holdings, net assets and monthly returns come from the fund's N-PORT filing with the SEC, as of May 31, 2026 (filed Jul 24, 2026). The expense ratio is from the fund's prospectus or shareholder report, as of Sep 30, 2025. Prices are generated sample data for development. Data sources and disclosures